Recipharm AB
Recipharm develops and manufactures inhalation products and devices including integrated drug solutions, medical check valves and injection devices. Whether you’re a big pharma company outsourcing a key stage of your production or a small to medium sized specialty firm seeking support in the development, transfer and production of a product, we’re a reliable option. Provides pharmaceutical development services, and manages Recipharm’s patents, technologies, and drug product rights, as well as the development and manufacturing of drug substance (Active Pharmaceutical Ingredient, API).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
By helping to manage the complexity of processes and projects, we reduce the risk for our clients.
Our company unites over 30 facilities across 10 different countries, offering a range of services across four business segments:
MANUFACTURING: STERILES
Manufactures sterile products, including the use of lyophilisation and blow-fill-seal (BFS) technologies.
MANUFACTURING: SOLIDS & OTHERS
Manufactures non-sterile products, including tablets, capsules, semi-solids, liquids and powders but excluding inhalation products.
Our Vision and Mission
To be acknowledged as the best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry by our customers, employees and other stakeholders.
OUR MISSIONRecipharm offers its expertise and facilities in the development, production and supply of pharmaceuticals to demanding customers for global use.
Recipharm also:
- Contributes to the improvement of health and care for the environment
- Rewards success, encourages personal and professional development and offers exciting challenges and participation in the company's development
- Is characterised by: pride in the company, high quality standards, creativity and delivering on promises
Our Strategies
SUPPLYING INNOVATIVE EXPERTISE
The key factors that allow us to meet customer expectations are extensive pharmaceutical knowledge and expertise accumulated throughout our long history, including advanced technologies and delivery systems, that creates customer value. This provides us with competitive advantages to meet increasing customer expectations.
A GLOBAL DEVELOPMENT SERVICES OFFERING
Supporting customers to develop new products and market access allows us to generate sustained organic growth by securing recurrent manufacturing services. Our development services combined with a global supply footprint aligns with all kinds of customers, from start-ups and specialty pharma to large pharmaceutical companies.
INCREASING OUR SHARE OF THE VALUE CHAIN
We develop our service offering in line with customer needs and how we can best create value.
By combining services such as drug substance and formulation development with commercial supply and advanced delivery systems, we accelerate the development process and simplify supply chains. Additionally, we assist with regulatory support to further improve time-to-market for commercial launches in multiple countries and regions. Recipharm is also increasingly drawing on opportunities to include its own Intellectual Property (IP) in its customers offering.
CONSOLIDATING THE CDMO INDUSTRY
We have a proven track record of company acquisitions, which allows us to develop our existing capabilities with new assets and expertise that complement our offering. Our acquisition targets include competitors but also asset-backed manufacturing partnerships with pharmaceutical companies that wish to externalise the manufacturing of some products associated with the transfer of manufacturing assets.
STREAMLINING OPERATIONS
At every stage of a project, we strive to optimise operations, effectively utilise resources and maximise efficiency by implementing lean methods throughout the organisation. Sustainable development is also a priority area for us as we constantly review our activities in a way that reduces our impact on the environment and our stakeholders.
EMPLOYING EXCELLENT PEOPLE
Operating in a competitive environment and supplying highly demanding customers requires talented people and it is vital to attract, develop and retain excellent individuals. We promote and nurture talent internally through internal recruitment, development and promotion. This creates exciting opportunities for our people to develop their skills, excel and grow within our organisation.
Customers
We proudly support pharmaceutical companies of all sizes with their outsourced development and manufacturing needs. Our clients are the lifeblood of our business, which is why we look after every single one of them regardless of their stage in the drug lifecycle.
Our clients are situated all over the world and their products are supplied globally.
Today, we have more than 400 customers. By continuously diversifying our range of dosage forms, technologies and geographies we are gaining the opportunity to extend relationships with existing customers whilst generating new business.
As customer focus and long-term relationships are a high priority for Recipharm, we always treat customers in a fair and professional manner at all times. Due to the high transfer costs and complexity involved in drug development projects, it is vital for customers to carefully select partners that they can trust for a successful business relationship. This is what Recipharm is all about and why we have enjoyed such stability with our customer base.
If you’re interested in becoming a customer, contact us today.
Company History
Our company began its journey back in 1995 with the management buyout of a solid dose facility in Stockholm, including a portfolio of around 20 well-known pharmaceutical products.
Lars Backsell and Thomas Eldered, who were both employees of the selling company, got together to form the company ‘Recip’. With Lars’ market and product development experience and Thomas’ in-depth knowledge of manufacturing and the facility, they complemented each other well from day one.
An innovative strategyIt took a few years for Recip to develop its current CDMO strategy. In 1995, the pharmaceutical industry was prospering from the many profitable products it had developed during the 1980s and cost saving measures, such as outsourcing, had not yet become a priority.
Recip was the first pharmaceutical company in the world to ISO 14001 certify its entire operations, and an extensive environmental policy gave the company a competitive edge and strong values. This environmental profile remains an important part of Recipharm today and our customers appreciate the benefits of working with a CDMO that guarantees high sustainability standards.
A CDMO is bornIn 2001, the brand name Recipharm was established for the growing contract manufacturing part of Recip’s business. Six more facilities were acquired between 2001 and 2007 which added capacity, new advanced technologies, more diverse dosage forms and a growing network of customers.
In 2007, in line with the changing marketplace, the company decided to dedicate itself fully to the outsourcing business. The rights to products were sold, but its valuable development expertise and experience were retained in-house. Our position as a pure CDMO was established as we continued to develop the ‘Recipharm’ brand through further acquisitions.
A growth storySince then Recipharm has grown quickly and in order to continue our growth strategy, the business was listed on the Stockholm Stock Exchange in April 2014. Three new important acquisitions were made in the same year. Milano based Corvette Pharmaceutical Services Group was acquired from LBO Italia Investimenti, Portuguese CMDO Lusomedicamenta Sociedade Técnica Farmacêutica S.A was added to the Group and Recipharm acquired a Flamel Technologies development facility in Pessac, France.
2015 saw the acquisition of Uppsala based OnTarget Chemistry, strengthening our development services offering. By the end of 2015, a facility from Alcon in France was acquired, adding the important blow-fill-seal technology to Recipharm's services offering. In October 2015, Recipharm announced its intention to acquire a majority stake in Indian CMO Nitin Lifesciences, creating a platform for emerging markets. The deal was finalised in April 2016, and Recipharm acquired the remaining shares in Nitin Lifesciences Limited in January 2018.
In March 2016, Recipharm acquired the Italian based CDMO Mitim to further develop its offering within beta lactams. In April 2016, Recipharm announced the strategic acquisitions of Kemwell's CDMO businesses in the US, Sweden and in India creating a leading global CDMO. The acquisition of the US and Swedish operations was finalised in May, and the acquisition of the Indian operations was finalised in February 2017.
In December 2017, Recipharm completed the acquisition of the Roche manufacturing facility in Leganés, Spain, signing a long-term agreement with a major new customer.
In October 2018, Recipharm completed the acquisition of the Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK.
In February 2020, Recipharm completed its largest acquisition to date. The acquisition of the UK listed company Consort Medical made Recipharm into one of the largest CDMOs in the world in terms of revenue. The acquisition complements Recipharm’s business and presents opportunities to develop its customer offering – such as in device development and manufacturing.
Today, Recipharm remains headquartered in Sweden and now includes around 30 manufacturing and development facilities in Europe, India, Israel and North America. The company is one of the oldest and most experienced CDMOs in the world and we are proud of what we have achieved. In the interests of all our stakeholders – long may this success continue.